Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
作者机构：Department of Internal MedicineNYU Grossman School of MedicineNew YorkNY 10016United States Department of Interventional RadiologyMemorial Sloan Kettering Cancer CenterNew YorkNY 10065United States Division of Hematology and OncologyPerlmutter Cancer Center of NYU Langone HealthNYU School of MedicineNew YorkNY 10016United States
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2022年第28卷第23期
页 面：2561-2568页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Chemoembolization Hepatocellular carcinoma Immunotherapy Drug combinations Review Medical oncology
摘 要：Barcelona clinic liver cancer(BCLC)intermediate stage hepatocellular carcinoma is a heterogenous *** chemoembolization is offered as the first line therapy in this disease *** advances in systemic therapy have markedly improved outcomes even in advanced stage *** use of systemic therapy in BCLC intermediate stage disease may now be of therapeutic benefit in selected *** will focus on“the up to sevencriteria and its utility in selecting systemic therapy.
维普期刊数据库